Simvastatin reverses target organ damage and oxidative stress in angiotensin II hypertension: Comparison with apocynin, tempol, and hydralazine

Journal of Cardiovascular Pharmacology

Volumn 50, Issue 3, 2007, Pages 293-298

  Rugale, Caroline ^a   Delbosc, Sandrine ^a   Mimran, Albert ^a   Jover, Bernard ^a  

^a UNIV MONTPELLIER   (France)

Author keywords

Albuminuria; AOPP; Cardiac hypertrophy; Superoxide anion; Vascular hypertrophy

Indexed keywords

ANGIOTENSIN II; APOCYNIN; ELECTROLYTE; HYDRALAZINE; SIMVASTATIN; SUPEROXIDE; TEMPOL;

ALBUMINURIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTERIAL PRESSURE; ARTICLE; CAROTID ARTERY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; HEART VENTRICLE HYPERTROPHY; HYPERTENSION; MALE; MORPHOMETRICS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; SPECTROPHOTOMETRY; TARGET ORGAN; TREATMENT OUTCOME;

ACETOPHENONES; ALBUMINURIA; ANGIOTENSIN II; ANIMALS; ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; ANTIOXIDANTS; CARDIOMEGALY; CAROTID ARTERIES; CYCLIC N-OXIDES; HYDRALAZINE; HYPERTENSION; MALE; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; SIMVASTATIN; SPIN LABELS; SUPEROXIDES; TUNICA MEDIA;

EID: 34548721060     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3180a72606     Document Type: Article

References (50)

1. Drayer J, Weber MA, De Young DL. Blood pressure as a determinant of cardiac left ventricular muscle mass. Arch Int Med. 1983;142:90-92.
2. Baker KM, Aceto JF. Angiotensin II stimulation of protein synthesis and cell growth in chick heart cells. Am J Physiol Heart Circ Physiol. 1990;259:H610-H618.
3. Sadoshima JI, Izumo S. Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype. Circ Res. 1993;73:413-423.
4. Crawford DC, Chobianan AV, Brecher P. Angiotensin II induces fibronectin expression associated with cardiac fibrosis in the rat. Circ Res. 1994;74:727-739.
5. Susic D, Nunez E, Frohlich ED, et al. Angiotensin II increases left ventricular mass without affecting myosin isoform mRNAs. Hypertension. 1996;28:265-268.
6. 1 receptor. Am J Hypertens. 1992;5:276-280.
7. Griendling KK, Minieri CA, Ollerenshaw JD, et al. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res. 1994;74:1141-1148.
8. Wolf G. Free radical production and angiotensin. Curr Hypertens Rep. 2000;66:167-173.
9. Laursen JB, Rajagopalan S, Galis Z, et al. Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circulation. 1997;95:588-593.
10. Rugale C, Delbosc S, Cristol JP, et al. Sodium restriction prevents cardiac hypertrophy and oxidative stress in angiotensin II hypertension. Am J Physiol Heart Circ Physiol. 2003;284:H1744-H1750.
11. Rugale C, Cordaillat M, Mimran A, et al. Prevention and reversal by enalapril of target organ damage in angiotensin II hypertension. J Renin Angiotensin Aldosterone Syst. 2005;6:154-160.
12. Delbosc S, Cristol JP, Descomps B, et al. Simvastatin prevents angiotensin II-induced cardiac alteration and oxidative stress. Hypertension. 2002;40:142-147.
13. Li JM, Gall NP, Grieve DJ, et al. Activation of NADPH oxidase during progression of cardiac hypertrophy to failure. Hypertension. 2002;40:477-484.
14. Wagner AH, Köhler T, Rückschloss U, et al. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol. 2000;20:61-69.
15. Wassmann S, Laufs U, Baumer AT, et al. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol. 2001;59:646-654.
16. Delbosc S, Morena M, Djouad F, et al. Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, are able to reduce superoxide anion production by NADPH oxidase in THP-1derived monocytes. J Cardiovasc Pharmacol. 2002;40:611-617.
17. Ortiz MC, Manriquez MC, Romero JC, et al. Antioxidants block angiotensin II-induced increase in blood pressure and endothelin. Hypertension. 2001;38:655-659.
18. Asaba K, Tojo A, Onozato ML, et al. Effects of NADPH oxidase inhibitor in diabetic nephropathy. Kidney Int. 2005;67:1890-1898.
19. Jin L, Beswick RA, Yamamoto T, et al. Increased reactive oxygen species contributes to kidney injury in mineralocorticoid hypertensive rats. J Physiol Pharmacol. 2006;57:343-357.
20. Cotter MA, Cameron NE. Effect of the NAD(P)H oxidase inhibitor, apocynin, on peripheral nerve perfusion and function in diabetic rats. Life Sci. 2003;73:1813-1824.
21. Ben-Shaul V, Lomnitski L, Nyska A, et al. The effect of natural antioxydants, NAO and apocynin, on oxidative stress in the rat heart following LPS challenge. Toxicol Lett. 2001;123:1-10.
22. 2 leads to hypertension. Hypertension. 2003;42:25-30.
23. B receptor blockade in rats on a high-salt diet. Hypertension. 2004;44:770-775.
24. Clozel JP, Kuhn H, Hefti F. Decreases of vascular hypertrophy in four different types of arteries in spontaneously hypertensive rats. Am J Med. 1989;87:92S-95S.
25. Witko-Sarsat V, Allen RC, Paulais M, et al. Disturbed myeloperoxidase-dependent activity of neutrophils in cystic fibrosis homozygotes and heterozygotes, and its correction by amiloride. J Immunol. 1996;157:2728-2735.
26. Witko-Sarsat V, Friedlander M, Nguyen Khoa T, et al. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol. 1998;161:2524-2532.
27. Cordaillat M, Rugale C, Casellas D, et al. Cardiorenal abnormalities associated with high sodium intake: correction by spironolactone in rats. Am J Physiol Regul Integr Comp Physiol. 2005;289:R1137-R1143.
28. Wilson TW, Alonso-Galicia M, Roman RJ. Effects of lipid-lowering agens in the salt-sensitive rat. Hypertension. 1998;31:225-231.
29. Jiang J, Roman RJ. Lovastatin prevents development of hypertension in spontaneously hypertensive rats. Hypertension. 1997;30:968-974.
30. Susic D, Varagic J, Ahn J, et al. Beneficial pleiotropic vascular effects of rosuvastatin in two hypertensive models. J Am Coll Cardiol. 2003;42:1091-1097.
31. Kase H, Hashikabe Y, Uchida Y, et al. Supplementation with tetrahydrabiopterin prevents the cardiovascular effects of angiotensin-II induced oxidative and nitrosative stress. J Hypertens. 2005;23:1375-1382.
32. Pech V, Sikka SC, Sindhu RK, et al. Oxidant stress and blood pressure responses to angiotensin II administration in rats fed varying salt diets. Am J Hypertens. 2006;19:534-540.
33. Wu R, Laplante MA, de Champlain J. Prevention of angiotensin II-induced hypertension, cardiovascular hypertrophy and oxidative stress by acetylsalicylic acid in rats. J Hypertens. 2004;22:783-801.
34. Chu Y, Piper R, Richardson S, et al. Endocytosis of extracellular superoxide dismutase into endothelial cells: role of the heparin-binding domain. Arterioscler Thromb Vasc Biol. 2006;26:1985-1990.
35. Waelti ER, Barton M. Rapid endocytosis of copper-zinc superoxide dismutase into human endothelial cells: role for its vascular activity. Pharmacology. 2006;78:198-201.
36. Erker L, Schubert R, Elchuri S, et al. Effect of the reduction of superoxide dismutase 1 and 2 or treatment with a-tocopherol on tumorigenesis in Atm-deficient mice. Free Radic Biol Med. 2006;41:590-600.
37. Virdis A, Neves MF, Amiri F, et al. Role of NAD(P)H oxidase on vascular alterations in angiotensin II-infused mice. J Hypertens. 2004;22:535-542.
38. Luo JD, Zhang WW, Zhang GP, et al. Effects of simvastatin on activities of endogenous antioxidant enzymes and angiotensin-converting enzyme in rat myocardium with pressure-overload cardiac hypertrophy. Acta Pharmacol Sin. 2002;23:124-128.
39. phox-containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice. Circulation. 2002;105:293-296.
40. 2 in angiotensin II-induced vascular hypertrophy. Hypertension. 1998;32:488-495.
41. Virdis A, Neves MF, Amiri F, et al. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension. 2002;40:504-510.
42. Kamide K, Rakugi H, Higaki J, et al. The renin-angiotensin and adrenergic nervous system in cardiac hypertrophy in fructose-fed rats. Am J Hypertens. 2002;15:66-71.
43. Witko-Sarsat V, Nguyen-Khoa T, Jungers P, et al. Advanced oxidation protein products as a novel molecular basis of oxidative stress in uraemia. Nephrol Dial Transplant. 1999;14:76-78.
44. Nakamura K, Fushimi K, Kouchi H, et al. Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-α and angiotensin II. Circulation. 1998;98:794-799.
45. 2. Hypertension. 2005;46:732-737.
46. Park JK, Müller DN, Mervaala EMA, et al. Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure and cholesterol-lowering effects. Kidney Int. 2000;58:1420-1430.
47. kip1 and induction of cellular hypertrophy in renal tubular cells depend on the generation of oxigen radicals. Kidney Int. 1998;54:1923-1933.
48. Johnson RJ, Lovett D, Lehrer RI, et al. Role of oxidants and protease in glomerular injury. Kidney Int. 1994;45:352-359.
49. Hayden MR, Chowdhury NA, Cooper SA, et al. Proximal tubule microvilli remodeling and albuminuria in the Ren2 transgenic rat. Am J Physiol Renal Physiol. 2007;292:F861-F867.
50. Kobayashi M, Sugiyama H, Wang DH, et al. Catalase deficiency renders remnant kidneys more susceptible to oxidant tissue injury and renal fibrosis in mice. Kidney Int. 2005;68:1018-1031.